New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
10:34 EDTTKPYY, APRIApricus Biosciences reports Takeda accepts first shipment of Vitaros
Apricus Biosciences (APRI) announced earlier that Takeda Pharmaceuticals (TKPYY), the company's partner in the United Kingdom, has accepted the first shipment of Vitaros, Apricus' topical treatment for erectile dysfunction. Apricus CEO Richard Pascoe said, "With the commercial availability of Vitaros in the United Kingdom, Takeda is in a position to finalize its pre-launch activities in an effort to be the first Vitaros commercial partner to offer an on demand topical cream treatment for men with erectile dysfunction." Shares of Apricus are up about 16% to $2.34 in morning trading.
News For APRI;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
07:35 EDTAPRIApricus Biosciences appoints Barbara Troupin, M.D. as Chief Medical Officer
Subscribe for More Information
December 8, 2014
16:03 EDTAPRIApricus Biosciences files to sell 3.42M share for selling stock holder
Subscribe for More Information
December 7, 2014
13:23 EDTTKPYYSeattle Genetics, Takeda announce four-year data from ADCETRIS trial
Subscribe for More Information
12:44 EDTTKPYYSeattle Genetics, Takeda report Phase 3 AETHERA trial data from Adcetris
Subscribe for More Information
12:33 EDTTKPYYTakeda formalizes 'Takeda Oncology' to meet needs of cancer patients
Takeda Pharmaceutical announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda Oncology. The creation of Takeda Oncology will improve the company’s ability to meet the unique and urgent needs of cancer patients, their loved ones and health care providers worldwide. Takeda will sustain its long-standing entrepreneurial approach to oncology research and development while expanding its global commercial network and resources as Takeda Oncology. Takeda is retiring the Millennium: The Takeda Oncology Company brand, and replacing it with Takeda Oncology to reflect the new global oncology business unit. “Despite the progress made in the fight against cancer, serious unmet needs persist across many forms of the disease,” said Christophe Bianchi, M.D., President, Global Oncology Business Unit. “Takeda Oncology has a deep understanding of patient needs and applies scientific rigor and resources to work to meet these needs. Now, our agile business model optimally organizes us to quickly meet the diverse needs of cancer patients, health care providers and systems around the world, and bring the next generation of cancer treatments to cancer patients who need them.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use